Abingworth Appoints Dr Shelley Chu as Partner

LONDON and MENLO PARK, California, October 19, 2015 /PRNewswire/ --

Abingworth, the international investment group dedicated to life sciences, today announced that Shelley Chu, MD, PhD has joined Abingworth as a Partner. Shelley, who brings more than 20 years of experience in venture capital, business development and strategic leadership, will source and manage deals across a broad range of therapeutic areas and stages of development from start-ups to late-stage investments.

Shelley joins Abingworth from Gilead Sciences where she led Business Development in Oncology, Immunotherapy and Hepatitis B, as well as R&D Strategy. Previously, Shelley held the position of Principal at Frazier Healthcare Ventures and, earlier in her career, was an investment professional at Flagship Ventures and a consultant at McKinsey. Shelley holds a Doctorate of Medicine and a PhD in Biochemistry and Biophysics from the University of California, San Francisco. She is a first author of publications in Science and other prominent journals.

"We are delighted to welcome Shelley to our global team," said Kurt von Emster, Managing Partner. "Her extensive venture capital experience and strategic corporate development experience at Gilead, combined with her expansive network across the life sciences industry, is exceptional and will provide Abingworth new sources of deal flow and scientific and clinical insights."

"I am excited to join a global leader in life science investing with its expertise and commitment," said Shelley Chu. "I look forward to building on Abingworth's success and helping advance novel therapeutics to improve patients' lives."

Shelley will be located in Abingworth's Menlo Park office.

Notes for Editors 

About Abingworth 

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life science sectors.

Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park (California) and Boston, Abingworth has invested in more than 135 life science companies, completed 60 IPOs and 41 mergers and acquisitions.

http://www.abingworth.com

SOURCE Abingworth